)
Ella Foundation, which has taken up research for finding a potential vaccine for the deadly Ebola virus, today said it had successfully completed preliminary studies on the virus, which was responsible for high fatalities among humans in central Africa.
The Hyderabad-based foundation said it had completed the preliminary animal (with mice) experiments of the virus’ glycoprotein with the targeted adenovirus, and the “immune response results have been good”, which would be followed by toxicology tests and the subsequent clinical trials involving human beings.
Adenoviruses are responsible for respiratory infections, gastroenteritis, cystitis, and primary pneumonia in humans, and are therefore used as a clear target to understand the human immunity characteristics in laboratory. However, the efficacy of the vaccine is judged by the outcomes seen in human trials.
Speaking on the development, Nagendra Hegde, group leader of research at Ella, said, for the next level research outcomes, the “Indian government should come forward, as finding a vaccine for cure against Ebola is of national interest.”
He said that India was not actively pursuing research for Ebola drug discovery, adding China was currently pitching for African nationals residing in the country to become volunteers for human trials.
In a presentation to mediapersons today, he stated that as of April 22, globally there were 261,000 suspected Ebola-affected humans, with 14,880 laboratory confirmed cases, and around 11,000 deaths, most of which were in central Africa, according to the World Health Organisation (WHO).
Terming it as a “multi-organ disease”, Hegde said the virus could spread fast through human touch, and a better part of the world, including India, is at risk of the deadly virus.
Across the world, multinational pharma majors, including GlaxoSmithKline, Johnson & Johnson, Merck and Novavax are involved in spearheading the research, with committed budgets of close to $500 million, he said.
Earlier, Ella Foundation had helped Bharat Biotech in the development of H1N1 pandemic influenza in the early stage.
